U.S. markets close in 5 hours 36 minutes

Provention Bio to Report First Quarter 2020 Financial Results and Host Conference Call on Thursday, May 7, 2020

OLDWICK, N.J., April 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will report its first quarter 2020 financial results on Thursday, May 7, 2020.

(PRNewsfoto/Provention Bio, Inc.)

In connection with the earnings release, Provention's management team will host a live conference call and webcast at 4:30 PM ET on Thursday, May 7, 2020, to discuss the Company's financial results and provide a business update.

Conference Call Information
To access the call, please dial 1-877-870-4263 (domestic) or 1-412-317-0790 (international) five minutes prior to the start time and ask to be connected to the "Provention Bio Call." An audio webcast will also be available on the "Events and Webcasts" page of the Investors section of the Company's website, www.proventionbio.com.  An archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for seven days following the call. 

About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a clinical-stage biopharmaceutical company leveraging a transformational drug development strategy focused on the prevention or interception of immune-mediated disease. Provention's mission is to source, transform and develop therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune diseases. Provention's diversified portfolio includes PRV-031 (teplizumab), a pre-commercial-stage candidate that has been shown to delay the onset of end-stage type one diabetes (T1D) in at-risk individuals with pre-symptomatic disease.  The Company's portfolio includes additional clinical-stage product development candidates that have demonstrated proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.

Investors:
Sam Martin, Argot Partners
sam@argotpartners.com   
212-600-1902

Media:
Lori Rosen, LDR Communications
lori@ldrcommunications.com 
917-553-6808

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-report-first-quarter-2020-financial-results-and-host-conference-call-on-thursday-may-7-2020-301049974.html

SOURCE Provention Bio, Inc.